



Date: 9 December 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NYRADA INC. – LODGEMENT OF SUPPLEMENTARY PROSPECTUS

Sydney, 9 December 2019: Noxopharm Limited (ASX: NOX) advises that its subsidiary, Nyrada Inc. (**Nyrada**), has today lodged a supplementary prospectus (**Supplementary Prospectus**) with ASIC. The Supplementary Prospectus is to be read with the prospectus dated 26 November 2019 issued by Nyrada (which was released by Noxopharm on ASX on 26 November 2019).

The Supplementary Prospectus is attached to this notice.

.....

About Nyrada

Nyrada is a U.S. company registered as a foreign company in Australia. Nyrada is a pre-clinical stage, drug discovery and development company specializing in novel small molecule drugs pertaining to cardiovascular, neurological and chronic inflammatory diseases. The Company's two leading R&D programs are (i) an oral PCSK9-inhibitor (cholesterol-lowering drug), and (ii) a neuroprotectant to limit brain damage following stroke and traumatic brain injury.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company focusing on oncology drugs with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® for the treatment of late-stage cancers including prostate cancer and sarcomas and is the major shareholder in Nyrada Inc.

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 9299 9690

E: David.Franks@automicgroup.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

**NYRADA INC.
ARBN 625 401 818**

SUPPLEMENTARY PROSPECTUS

1. Supplementary Prospectus

This document is a supplementary prospectus (**Supplementary Prospectus**) to the prospectus dated 26 November 2019 (**Prospectus**) issued by Nyrada Inc. ARBN 625 401 818 (**Company**).

This Supplementary Prospectus is dated 9 December 2019, and was lodged with ASIC on that date. Neither ASIC, ASX nor any of their respective officers or employees take any responsibility for the content of this Supplementary Prospectus.

This Supplementary Prospectus should be read together with the Prospectus. If there is a conflict between the Prospectus and this Supplementary Prospectus, this Supplementary Prospectus prevails. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus.

The Company has issued both a printed and electronic version of this Supplementary Prospectus and the Prospectus. Electronic versions of both may be accessed at <https://www.nyrada.com/site/content/>.

This Supplementary Prospectus and the Prospectus are important documents and should be read in their entirety. If you do not understand this Supplementary Prospectus and the Prospectus, you should consult your professional advisers without delay.

2. Amendments to the Prospectus

The exercise price of the Options to be issued to holders of Convertible Notes in Section 11.2 of the Prospectus is incorrectly stated to be \$2.0138. The correct exercise price for these Options is \$0.20 (which is equal to the Offer Price). This will apply to 1,725,656 Options that are to be granted to the holders of Convertible Notes upon the Company's admission to the Official List (if such admission occurs prior to 31 January 2020).

This amendment is a correction and the Directors do not believe that this amendment is materially adverse from the point of view of an investor.

3. Approval of Supplementary Prospectus

The issue of this Supplementary Prospectus by the Company has been duly authorised by a resolution of the Directors.

Each Director has consented to the lodgement of this Supplementary Prospectus with ASIC in accordance with section 720 of the Corporations Act and has not withdrawn his consent prior to lodgement.

Dated: 9 December 2019

Signed for and on behalf of Nyrada Inc.

A handwritten signature in black ink, appearing to read "John Moore". The signature is written in a cursive style with a large initial "J" and a distinct "M".

John Moore
Non-Executive Chairman
Nyrada Inc.